Dyax Corp. (NASDAQ: DYAX) is focused on discovering, developing, and commercializing novel biopharmaceuticals for medical needs that are currently unmet. The company hopes to meet its objectives while delivering outstanding value to patients and stockholders. Their produce candidates include fully human monoclonal antibodies in addition to small proteins and peptides. For further information, visit the Company’s web site at www.dyax.com.
- 17 years ago
QualityStocks
Dyax Corp. (NASDAQ: DYAX)
Tags Rodman & Renshaw
Related Post
-
New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Looks Forward to Bolivia Presidential Runoff, Hoping for Increased Foreign Investment Support
Bolivia heads into an October presidential runoff, signaling a possible shift toward more pro-business policies,…
-
Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF): Building Value Through Nevada’s Walker Lane
Four-property portfolio in Nevada’s Walker Lane anchored by the Santa Fe Mine project with over…
-
ONAR Holding Corp. (ONAR) Powers Smarter Marketing with Agency Innovation
As budgets tighten and demands intensify, CMOs are questioning traditional marketing models ONAR is seizing…